Toxin is not just for wrinkles anymore. A May study formalized micro botulinum toxin, injecting hyperdilute toxin into the skin to target pores, texture, and acne, using products providers already know.
A May 2026 study published in Facial Plastic Surgery formalized micro botulinum toxin therapy (MBT, or microtox): intradermal injection of hyperdilute botulinum toxin across the face, neck, and chest to improve skin quality, including pores, texture, acne, and aging. It uses existing FDA-approved toxins off-label, requiring proper training, consent, and dilution protocols.
Botulinum toxin built its reputation relaxing frown lines, but a quieter use targets the skin itself.
A May study gave that approach a clearer clinical framework.
A study published in Facial Plastic Surgery in May 2026 introduced micro botulinum toxin therapy (MBT), the intradermal injection of hyperdilute botulinum toxin across the face, neck, and chest to promote repair at the skin surface and dermal levels. Reported applications include active acne, acne scarring, enlarged pores, skin texture, and generalized cutaneous aging. According to the published abstract, the technique requires no specialized equipment, is applicable to all Fitzpatrick skin types, and carries minimal risk beyond rare temporary muscle weakness (paresis).
Importantly, MBT uses existing FDA-approved botulinum toxin products off-label, meaning it is a technique rather than a new product. The evidence base is described as still early. For providers, the gating factors are training, documented informed consent, and a clear grasp of dilution protocols, not access to a novel drug.
For consumers, microtox represents toxin used for skin quality rather than muscle movement, a different goal with a different, more superficial technique. Because it is off-label and early-evidence, expectations should be measured and the provider experienced. The honest framing is promising, increasingly formalized, but not a guaranteed or standardized treatment, and results vary by technique, dilution, and individual.
Watch for larger, controlled studies that strengthen the evidence and standardize protocols, which would move microtox from emerging technique toward established practice. As interest grows, so does variability in how it is performed. For patients, the practical step is to ask how a provider dilutes and places the product, what evidence supports it for their specific concern, and to recognize that off-label use should come with clear informed consent.